There were 1,093 press releases posted in the last 24 hours and 400,678 in the last 365 days.

The Proscere Bioscience Division of Simlatus to Close Export CBD Deal in Europe -- a $225M Market Expectation

San Francisco, California, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK:SIML) (“Simlatus” or the “Company”) announces that its CBD division, Proscere Bioscience, has reached a closing date on or before March 31, 2019 with a Swiss-based CBD company.  

Proscere Bioscience manufactures and distributes commercial cold-water CBD extraction systems. This advanced method and technology is highly effective in producing medical-grade CBD.

Richard Hylen further stated, “Our CBD extraction systems range from $750,000 for a high-end commercial system capable of 3000 gallons per day, to our low-end model costing $400,000. The company in Switzerland will receive an exclusive 5 year license with sell volume discounts of up to $50M per year. Europe is already a fertile ground for hemp and it’s growing fast thanks to the increasing consumption of other hemp-based products. In 2016, 33,000 hectares of hemp were cultivated on the continent, which equals about 81,500 acres. In the same year, the United States grew 9,650 acres.”

Mr. Hylen further stated, “Our European target is the large pharmaceutical companies. Epidiolex, which is CBD based, is used to treat seizures. CBD can be used to help people suffering with a wide range of ailments. From treating pain, inflammation, infections, sleep issues and mood disorders. CBD is also proven to support the immune system, protects the brain and fights cancer. Our commercial cold-water CBD extraction system is expected to yield $225M over the next 5 years, based upon expected growth and application.”   

Safe Harbor for Forward-Looking Statements: This news release contains forward-looking statements which are not statements of historical fact. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to changes in general economic and financial market conditions. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.


Richard Hylen, CEO

Tel: (530) 205-3437